GUIDANT ACS Rx MULTI-LINK HAS 70% U.S. STENT MARKET DOLLAR VOLUME; EVEREST MEDICAL ATTRIBUTES 10% OF FOURTH-QUARTER VOLUME TO GUIDANT VASOVIEW BUSINESS
This article was originally published in The Gray Sheet
Sales of Guidant's ACS Rx Multi-Link stent, launched on Oct. 2, topped $200 mil. in the fourth quarter of 1997, the company reported Feb. 3. According to Guidant President and CEO Ronald Dollens, who spoke the same day at a Piper Jaffray investor conference in New York City, the product now accounts for roughly 70% of the dollar volume and 60% of the unit volume of a U.S. stent market that is rapidly approaching an estimated $1 bil.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Series C investment of an undisclosed amount announced in early May follows $20m funding for the Los Angeles company from Volition Capital and angel investors.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.